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Currently used hepatocyte cell systems for in vitro assessment of drug metabolism
include hepatoma cell lines and primary human hepatocyte (PHH) cultures. We
investigated the suitability of the validated in vivo Basel phenotyping cocktail (caffeine
[CYP1A2], efavirenz [CYP2B6], losartan [CYP2C9], omeprazole [CYP2C19], metoprolol
[CYP2D6], midazolam [CYP3A4]) in vitro and characterized four hepatocyte cell
systems (HepG2 cells, HepaRG cells, and primary cryopreserved human hepatocytes in
2-dimensional [2D] culture or in 3D-spheroid co-culture) regarding basal metabolism and
CYP inducibility. Under non-induced conditions, all CYP activities could be determined
in 3D-PHH, CYP2B6, CYP2C19, CYP2D6, and CYP3A4 in 2D-PHH and HepaRG, and
CYP2C19 and CYP3A4 in HepG2 cells. The highest non-induced CYP activities were
observed in 3D-PHH and HepaRG cells. mRNA expression was at least four-fold higher
for all CYPs in 3D-PHH compared to the other cell systems. After treatment with 20
µM rifampicin, mRNA increased 3- to 50-fold for all CYPs except CYP1A2 and 2D6
for HepaRG and 3D-PHH, 4-fold (CYP2B6) and 17-fold (CYP3A4) for 2D-PHH and
four-fold (CYP3A4) for HepG2. In 3D-PHH at least a two-fold increase in CYP activity
was observed for all inducible CYP isoforms while CYP1A2 and CYP2C9 activity did
not increase in 2D-PHH and HepaRG. CYP inducibility assessed in vivo using the same
phenotyping probes was also best reflected by the 3D-PHH model. Our studies show
that 3D-PHH and (with some limitations) HepaRG are suitable cell systems for assessing
drug metabolism and CYP induction in vitro. HepG2 cells are less suited to assess CYP
induction of the 2C and 3A family. The Basel phenotyping cocktail is suitable for the
assessment of CYP activity and induction also in vitro.
Keywords: cytochrome P450 (CYP), basel cocktail, 3-dimensional spheroid primary human hepatocyte culture,
CYP induction, liquid chromatography tandem mass spectrometry
INTRODUCTION
Cytochrome P450 enzymes (CYPs) are involved in the oxidative metabolism of the majority of the
commonly used low molecular weight drugs, thereby influencing the pharmacokinetics of these
drugs and having an important role in drug-drug interactions (Wilkinson, 2005). Genetic variants
and exogenous factors such as diet, smoking habits, and concomitant medication can affect the
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activity of CYPs. All of these factors are responsible for wide
interindividual variations in CYP activity and drug plasma
concentrations, which can be associated with either increased
toxicity or an insufficient pharmacological effect.
Simultaneous determination of the activity of different CYPs
in an individual patient can be performed by administering a
combination (“cocktail”) of specific probe drugs (Fuhr et al.,
2007). Several cocktails have been characterized in clinical studies
and are used in individual patients, including the Karolinska
cocktail (Christensen et al., 2003), the Cooperstown 5+1 cocktail
(Chainuvati et al., 2003), the Geneva cocktail (Bosilkovska et al.,
2014) and the Basel Cocktail (Donzelli et al., 2014). These
cocktails have also been shown to be valuable tools to assess
the capacity of drugs to induce or inhibit CYPs (Bosilkovska
et al., 2014; Derungs et al., 2016). Drug cocktails have also been
used to perform in vitro studies, in particular when assessing the
CYP inhibition and induction potential of chemical compounds
(Youdim et al., 2007; Mori et al., 2009; Spaggiari et al., 2014).
Suitable in vitro systems to assess drug metabolism are
mainly liver microsomes, hepatocarcinoma cell cultures (e.g.,
HepG2 and HepaRG cells) and primary human hepatocytes
(PHHs). Monolayer-grown PHHs or hepatocarcinoma cell-lines
are currently the gold standard for in vitro drug-drug interaction
and hepatotoxicity studies. However, monolayer hepatocyte
culture systems have major drawbacks. PHH cultures suffer from
a rapid loss of cell polarity and of specific hepatic functions,
which limits their applicability for drug metabolism experiments
to a few days. Furthermore, they exhibit a large variation in
cell functions, especially in CYP activities, as well as a variable
response to CYP inducers (Abadie-Viollon et al., 2010; Godoy
et al., 2013). In comparison, hepatocarcinoma cell line cultures
can be used over extended periods of time, but their metabolic
activity and response to CYP inducers are generally limited
(Donato and Castell, 2003). As an alternative to 2D cultures of
PHHs or hepatocarcinoma cell lines, a variety of different 3D liver
models are being explored, as they are thought to approximate
the in vivo tissue structure and cell behavior more closely (Godoy
et al., 2013; Roth and Singer, 2014).
Limited availability of phenotyping probe drugs is a frequent
limitation of published in vivo phenotyping cocktails. To
facilitate clinical application of phenotyping, we therefore
developed a new low-dose cocktail, which is based on probe
drugs that are widely used in clinical practice (Donzelli et al.,
2014). In a subsequent study, we characterized this cocktail in
healthymale subjects treated with a combination of different CYP
inhibitors and a CYP inducer (Derungs et al., 2016). Since we now
have a detailed in vivo characterization of this cocktail, it was of
interest to also test the cocktail in vitro. The two principle aims
of our investigation were therefore (i) to assess the performance
and usability of the Basel cocktail in vitro by comparing in vitro
with in vivo results and (ii) to assess the suitability of different
hepatocyte cell models for the investigation of drug metabolism
and CYP induction.
In order to accomplish these aims, we tested themetabolism of
the Basel cocktail (containing caffeine, metoprolol, omeprazole,
losartan, efavirenz, and midazolam) in HepG2 cells, HepaRG
cells, and primary cryopreserved human hepatocytes grown in
2D and in 3D culture under basal conditions and after CYP
induction with rifampicin. CYP induction achieved by rifampicin
in vitro could then be compared with the extent of in vivo CYP
induction.
MATERIALS AND METHODS
Chemicals and Reagents
8′-hydroxyefavirenz, efavirenz-d4, losartan, losartan-carboxylic
acid (E3174), losartan-d4, omeprazole, 5′-hydroxyomeprazole,
omeprazole-d3, metoprolol, α-hydroxymetoprolol, and
metoprolol-d7 were purchased from TRC (Toronto, Canada).
1′-hydroxymidazolam and midazolam-d6 were acquired
from Lipomed (Arlesheim, Switzerland), whereas rifampicin
and β-glucuronidase (type HP-2 from Helix pomatia) were
obtained from Sigma-Aldrich (Sigma- Aldrich Chemie GmbH,
Buchs, Switzerland). Midazolam (F. Hoffmann-La Roche,
Basel, Switzerland) and efavirenz (Merck, NJ, USA) were
kindly provided by the respective manufacturers. The chemical
structures of the probe drugs and their phase I metabolites
are provided in Supplementary Figure 2. Formic acid, HPLC
grade methanol, and HPLC grade water were purchased from
Merck (Darmstadt, Germany). Media used were purchased from
GIBCO (Lucerne, Switzerland).
Stock solutions, calibration, and quality control spiking
solutions were prepared in DMSO. Calibration standards and
quality controls were prepared by enriching the respective
medium with the corresponding spiking solutions. Internal
standard solutions containing the deuterated cocktail probe
drugs were prepared in methanol.
Cell Cultures
The human hepatoma cell line HepG2 was obtained from ATCC
(Manassas, VA, USA). HepG2 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; with 2 mM GlutaMAX R©,
1.0 g/l glucose and sodium bicarbonate) supplemented with 10%
(v/v) heat-inactivated fetal calf serum (FCS), and 10 mM HEPES
buffer, pH 7.2. In general, all cells were kept at 37◦C in a
humidified 5% CO2 cell culture incubator and passaged using
trypsin, while the cell number was determined using a Neubauer
hemacytometer. Viability was checked using the tryptan blue
exclusion method. For the experiments, HepG2 cells were seeded
at 10,000 cells/well in 96-well plates or 150,000 cells/well in
12-well plates.
HepaRG cells were purchased from Biopredic International
(Rennes, France) as undifferentiated cryopreserved cells with the
associated medium. Freshly split HepaRG cells were seeded at
9000 cells/well in 96-well plates and treated over the course of
the next 4 weeks as previously described (Aninat et al., 2006).
Primary cryopreserved human hepatocytes (Life
Technologies, Lot Hu8119, female donor) were plated at
50,000 cells/ well in collagen type-1 precoated 96-well plates
in William’s E medium supplemented with 10% FBS (v/v),
1% L-Glutamine 200 mM (v/v), 1% Pen Strep (v/v), 0.1%
dexamethasone 100 µM (v/v), and 0.1% insulin 100 µM (v/v)
and left to incubate at 37◦C, 95% humidity, 5% CO2.
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For the 3D-hepatocyte co-culture model originally described
by Ohkura et al. (2014), 3T3 fibroblast cells from Swiss albino
mouse embryo tissue (3T3 Balb/clone A31, ATCC product
number CCL 163) were seeded at a density of 8000 cells/well
in 96-well plates or at 40,000 cells/well in 24-well plates into
micro-patterned plates (Cell-able R©, Cosmo Bio USA Inc., CA,
USA) in Dulbecco’s Modified Eagle’s medium (DMEM; with
2mM GlutaMAX R©), supplemented with 10% FBS. The cells
were cultured in a 5% CO2, 95% air humidified environment
at 37◦C. After 2 days, cryopreserved human hepatocytes (Life
Technologies Lot Hu8119) were seeded at a density of 25,000
cells/well in the same 96-well plates containing the 3T3 cells
(or 125,000 cells/well in 24-well plates). The 3T3-cryopreserved
human hepatocyte co-culture was maintained for a minimum of
2 days to allow for spheroid formation, using the same medium
as for the conventional two-dimensional (2D) cryopreserved
hepatocyte culture.
Cryopreserved human hepatocyte preparations were only
used for experiments if their morphological characteristics and
viability (>85%) were acceptable.
Markers of CYP450 Activity
CYP activity was assessed by the addition of a CYP probe
drug cocktail consisting of caffeine (CYP1A2, 80 µM), efavirenz
(CYP2B6, 10 µM), losartan (CYP2C9, 14 µM), omeprazole
(CYP2C19, 17 µM), metoprolol (CYP2D6, 23 µM), and
midazolam (CYP3A4, 5 µM). The substrates were used at
concentrations close to their Km values previously published.
A previously developed liquid chromatography tandem
mass spectrometry (LC-MS/MS) method (Donzelli et al.,
2014) was used to analyze the phase I metabolites of the
probe drugs. Chromatographic separation was performed
on a Shimadzu HPLC system (Shimadzu AG, Reinach,
Switzerland) coupled to a triple quadrupole tandem mass
spectrometer (API4000, AB/MDS Sciex, Concord, Canada)
operating in positive electrospray ionization mode, except for 8′-
hydroxyefavirenz, which was detected in negative mode. Total
run time was 2.9 min. Inter-assay accuracy (determined as the
% bias) ranged from −10.7 to 9.8 and inter-assay precision
(determined as the CV%) was lower than 11.3 for all analytes.
The lower limit of quantification (LLOQ) was 0.25 ng/ml for
hydroxymetoprolol, 8-hydroxyefavirenz, 1′-hydroxymidazolam,
5-hydroxyomeprazole, E-3174, and 0.5 ng/ml for paraxanthine.
CYP450 Induction Experiments
Evaluation of mRNA Expression
HepG2 cells, HepaRG cells, 2D-cultured human hepatocytes,
and 3D-cultured human hepatocytes were seeded in 24-
well plates and treated for 48 h with rifampicin 20 µM.
Three hundred and fifty microliters of RLT buffer (Qiagen,
Hombrechtikon, Switzerland) was used to lyse the respective
hepatocytes, after which the lysate was transferred to Qiashredder
columns and centrifuged for 2 min at 13,000 rpm. From the
eluate, total RNA was extracted and purified according to the
manufacturer’s instructions (Qiagen, RNeasy mini extraction
kit). The concentration of the extracted RNA was measured
spectrophotometrically at 260 nm on a NanoDrop 2000 (Thermo
Fisher Scientific, Wohlen, Switzerland). cDNA was reverse-
transcribed from the isolated RNA using the Qiagen omniscript
system. For quantitative RT-PCR 10 ng cDNA was used. Forward
and reverse primers for all CYPs tested and endogenous
references, hypoxanthine phosphoribosyltransferase 1 (HPRT1)
and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
were purchased from Microsynth (Balgach, Switzerland; listed
in Table 1). RT-PCR was performed using SYBR green (Roche
Diagnostics, Rotkreuz, Switzerland) on an ABI PRISM 7700
sequence detector (PE Biosystems, Rotkreuz, Switzerland).
Quantification of mRNA expression levels was performed using
the comparative-threshold cycle method (Livak and Schmittgen,
2001).
Functional Assessment of CYP Induction
HepG2 cells, HepaRG cells, cryopreserved human hepatocytes,
as well as three-dimensionally seeded co-cultured cryopreserved
human hepatocyte spheroids, were cultured in a 5% CO2 and
95% air humidified atmosphere at 37◦C. Induction treatment
(rifampicin 20 µM) lasted for 72 h, with the medium being
changed every 24 h. Rifampicin stock solution was prepared in
DMSO and further diluted in the appropriate culture medium to
achieve a final DMSO concentration of 0.1% (v/v). Experimental
control culture wells were treated with solvent [DMSO, 0.1%
(v/v)] alone. Following induction treatment, CYP activity was
assessed by the addition of fresh medium containing the cocktail
probe drugs to the control and pre-treated cells. Substrates
were dissolved and serially diluted in DMSO to the required
concentrations. The final concentration of DMSO during the
cocktail incubation was 0.2% (v/v). At selected time points (0,
15, 30, 45, 60, 90, and 120 min) the incubation was stopped
by the addition of a threefold volume of ice-cold methanol
containing the respective internal standards. The bottom of
the wells was scraped using a pipette tip, after which the
TABLE 1 | Gene-specific primers for RT-PCR.
Target gene Organism Primer Sequence (5′–3′) Length (bp)
CYP1A2 Human Fw GGACAGCACTTCCCTGAGAG 20
Rev GCTCCTGGACTGTTTTCTGC 20
CYP2B6 Human Fw CAGTGAATTCAGCCACCAGA 20
Rev ATTTTGGCTCGGTCATGAAG 20
CYP2C9 Human Fw AGGAAAACGGATTTGTGTGG 20
Rev GGCCATCTGCTCTTCTTCAG 20
CYP2C19 Human Fw GGATTGTAAGCACCCCCTG 19
Rev TAAAGTCCCGAGGGTTGTTG 20
CYP2D6 Human Fw TGTGCCCATCACCCAGAT 18
Rev AAGGTGGAGACGGAGAAGC 19
CYP3A4 Human Fw TACACAAAAGCACCGAGTGG 20
Rev TGCAGTTTCTGCTGGACATC 20
HPRT1 Human Fw GGTCCTTTTCACCAGCAAGCT 21
Rev TGACACTGGCAAAACAATGCA 21
GAPDH Human Fw AGCCACATCGCTCAGACAC 19
Rev GCCCAATACGACCAAATCC 19
Frontiers in Pharmacology | www.frontiersin.org 3 November 2016 | Volume 7 | Article 443
Berger et al. Basel Cocktail In vitro
contents were transferred to an autosampler vial. After vigorous
shaking (10min) and centrifugation (3220 g, 30 min, 10◦C)
the supernatants were stored at −20◦C until quantification by
LC-MS/MS.
To determine the velocity of midazolam 1′-hydroxylation and
efavirenz 8′-hydroxylation, the entire content of the autosampler
vials were evaporated using a minivap microplate evaporator
(Porvair Sciences Ltd., King’s Lynn, Norfolk, UK). The analytes
were then resuspended in 45 µl of the respective culture
medium to which 5 µl (500 units) of β-glucuronidase was added.
Following a 12 h incubation at 37◦C, the reaction was terminated
by the addition of methanol, after which the samples were treated
as described above.
In vivo Assessment of CYP Induction
The in vivo characterization of the Basel cocktail has been
described in previous publications (Donzelli et al., 2014; Derungs
et al., 2016). Fifteen healthy volunteers were treated with 600mg
rifampicin per day for 7 days to induce CYP activity (Derungs
et al., 2016). Genotyping identified one subject as a CYP2D6
intermediate metabolizer (CYP2D6∗4/∗41) and another subject
as a CYP2C19 poor metabolizer (CYP2C19∗2/∗2). Data from
these two subjects were not included in the analysis for CYP2C19
(n = 14) and CYP2D6 (n = 14), respectively. Clearance ratios of
the probe drugs (induced vs. non-induced) were used to assess
the extent of CYP induction.
Data Analysis
CYP activities were determined as the respective metabolite
formation rates corresponding to the slope in the metabolite
concentration vs. time graphs. Metabolite concentrations were
quantified using standard curves of pure compounds as
previously described (Donzelli et al., 2014).
For induction experiments, formation rates were determined
and the fold change vs. the basal conditions was calculated as
the ratio of the metabolite formation rate in wells exposed to an
inducer and control wells.
Means were compared with the two-tailed Student’s t-test
using GraphPad Prism 6.0 (GraphPad Software, San Diego,
CA, USA). Data are presented as mean ± SEM unless stated
otherwise.
RESULTS
CYP mRNA expression and CYP activities were investigated
using four different liver cell cultures: HepG2 cells, HepaRG cells,
PHHs seeded two-dimensionally (2D), and primary hepatocytes
from the same donor in three-dimensional (3D) spheroid co-
culture.
Basal mRNA Expression of CYPs in the
Different Liver Cell Models
Basal CYP mRNA expression relative to GAPDH was detectable
in all cell systems investigated and was highest in 3D-cultured
PHHs (Figure 1). For HepG2 cells, the CYP mRNA expression
was lower than for every other cell system investigated. In
comparison to 3D-cultured PHHs, HepaRG cells showed a 4
times lower mRNA expression of CYP3A4 and 2C19, whereas
the mRNA expression of the other CYPs investigated was more
than 10 times lower. In 2D-cultured PHHs, CYP2C19 mRNA
expression was ∼4 times lower than in 3D-cultured hepatocytes,
whereas the mRNA expression of the other CYPs was more than
10 times lower.
Basal Metabolic Activity of the Liver Cell
Models Used
Experiments using single substrates instead of the entire cocktail
showed no mutual interactions between the probe drugs, except
for 10 µM efavirenz, which was associated with a 30% decrease
in CYP2C9 and a 20% decrease in CYP2C19 activity (results not
shown). For HepaRG and conventional hepatocyte incubations,
the use of 10 µM efavirenz was necessary, as lower efavirenz
concentrations did not yield quantifiable concentrations of 8′-
hydroxyefavirenz. All experiments were performed with the
entire cocktail, hence the slight inhibitory effect of efavirenz was
present in both conditions (basal and induced). In the in vivo
cocktail, this interaction had been avoided by using efavirenz at a
very low dose (Derungs et al., 2016).
Basal activities for all substrates investigated could be
determined in HepaRG cells, 2D- and 3D-cultured PHHs, but
not in HepG2 cells (Table 2). The highest activities were observed
for CYP3A4, CYP2C19, and CYP2D6 in 3D-cultured PHHs and
in HepaRG cells. In HepG2 cells, only activities of CYP3A4 and
CYP2C19 could reliably be determined; metabolite formation
remained below the limit of detection for the other CYPs.
TABLE 2 | Basal CYP activities.
Basal CYP activities
pmol/h/50,000 cells
HepG2 cells HepaRG cells 2D-cultured PHH 3D-cultured PHH
CYP1A2 nd (0.46 ± 0.02) (0.09 ± 0.01) 0.22 ± 0.02
0.932
CYP2B6 nd 0.33 ± 0.02 0.54 ± 0.04 2.11 ± 0.07
0.999 0.905 0.985
CYP2C9 nd (0.11 ± 0.01) (0.016 ± 0.002) 0.16 ± 0.01
0.854
CYP2C19 0.16 ± 0.01 18.5 ± 1.0 0.47 ± 0.04 3.7 ± 0.1
0.976 0.939 0.815 0.978
CYP2D6 nd 0.69 ± 0.06 0.25 ± 0.01 6.2 ± 0.3
0.823 0.950 0.935
CYP3A4 0.64 ± 0.04 85.6 ± 4.5 27.4 ± 1.5 60.4 ± 1.5
0.645 0.991 0.903 0.993
Basal CYP activity in HepG2, HepaRG, 2D-, and 3D-cultured primary cryopreserved
human hepatocytes (PHH). Primary human hepatocytes used for 2D- and 3D-cultures
were from the same batch of cryopreserved cells. Values presented are the metabolite
formation rates (see Figure 2) and the corresponding regression coefficients (r2 ) of
the metabolite-time curves. Metabolite concentrations were determined by LC-MS/MS.
Data are presented as mean ± SEM of at least three independent experiments. Values
in brackets are based on measurements of the last experimental time-point only,
concentrations of all earlier time-points were below LLOQ. nd = not determinable (i.e.,
lacking basal activity).
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FIGURE 1 | Basal mRNA expression of CYP1A2 (A), 2B6 (B), 2C9 (C), 2C19 (D), 2D6 (E), and 3A4 (F) in HepG2, HepaRG, 2D-, and 3D-cultured primary
cryopreserved human hepatocytes. mRNA expression was determined by rt-PCR as described in the Materials and Methods Section. Results are expressed as
mean ± SEM relative to GAPDH of at least three independent experiments. PHH, primary human hepatocytes.
Figure 2 shows the metabolite formation rates for the
two CYP isoforms (CYP2C19 and CYP3A4) with activity
in all four cell models using omeprazole and midazolam as
probe drugs. Metabolite accumulation was linear with time
up to 45 min for CYP3A4 and up to 1 h for CYP2C19,
respectively. The metabolite formation rates were highest
for HepaRG cells and lowest for HepG2 cells. Formation
rates in 3D-cultured primary hepatocytes were higher than
in 2D-cultures, illustrating a benefit of the 3D spheroid
co-culture.
Induced mRNA Expression of CYPs in Liver
Cell Models Exposed to Rifampicin
Liver cell models were exposed to 20 µM rifampicin for
48 h and mRNA expression of the 6 CYPs isoforms was
determined. In HepG2 cells, mRNA expression increased only
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FIGURE 2 | Basal activity of CYP2C19 and CYP3A4 assessed using formation rates of 5-hydroxyomeprazole (A) and 1′-hydroxymidazolam (B) in HepG2, HepaRG,
2D-, and 3D-cultured primary cryopreserved human hepatocytes. Primary hepatocytes were from the same batch of cryopreserved cells. Metabolite concentrations
were determined by LC-MS/MS. The corresponding velocities and regressions are given in Table 2. Data are presented as mean ± SEM of at least three independent
experiments. PHH, primary human hepatocytes.
for CYP3A4 (Figure 3). In HepaRG cells, mRNA expression
increased for CYP2B6, 2C9, 2C19, and 3A4, but not for
CYP1A2 and 2D6. A similar pattern of CYP induction
was obtained for 3D-cultured PHHs, showing induction
for CYP2B6, 2C9, 2C19, and 3A4, but not for CYP2D6
and 1A2. In comparison, when primary hepatocytes from
the same batch were cultured conventionally (2D), induced
mRNA expression could only be found for CYP3A4 and
CYP2B6.
Since rifampicin is only a weak inducer of CYP1A2,
we exposed 3D-cultured PHHs also to 3-methylcholanthrene,
which is a well-established in vitro CYP1A2 inducer (Morel
et al., 1990; Rodríguez-Antona et al., 2000). As shown in
Supplementary Figure 1, in 3D-cultured PHHs CYP1A2 mRNA
was induced ∼13 times by 3-methylcholathrene, which was also
reflected in an∼6 times higher production of paraxanthine from
caffeine.
CYP Activity after Treatment of Liver Cell
Models with Rifampicin
Metabolite formation was assessed after treatment of
liver cells with 20 µM rifampicin for 72 h. As shown in
Figure 4, treatment of 3D-cultured PHHs was associated
with increased metabolite formation by all tested CYP
isoforms. The metabolite production rates were linear for
at least 45 min (midazolam) and up to 120 min (caffeine and
efavirenz).
In agreement with the mRNA expression data after induction
with rifampicin and basal CYP activity, metabolite formation
could be determined for all substrates in HepaRG cells, and
in 2D- and 3D-cultured PHHs, but not in HepG2 cells
(Table 3). The highest activities were detected for CYP3A4
and CYP2C19 in 3D-cultured PHHs and in HepaRG cells. In
HepG2 cells, only activities of CYP3A4 and 2C19 could be
detected.
Comparison Rifampicin-Induced CYP
Activity In vitro and In vivo
Compared to baseline, CYP2C9 and CYP3A4 activities were
increased 1.5–2 times in HepG2 cells without reaching statistical
significance (Figure 5). In HepaRG cells, activities of CYP3A4,
CYP2D6, 2C19, and 2B6 were increased significantly, with the
exception of CYP2D6 matching well with the mRNA induction
data. An almost identical result was obtained for 2D-cultured
PHHs. In 3D-cultured PHHs, CYP activities of all inducible
CYP isoforms were increased at least two-fold after rifampicin
induction.
Treatment of healthy volunteers with rifampicin (Derungs
et al., 2016) was associated with an approximately seven-fold
induction of CYP3A4, a 14-fold induction of CYP2C19, a
doubling of CYP2C9 activity and an ∼1.7-fold increase in
CYP2B6 activity. When compared to the liver cell models
investigated, this pattern was reflected best by the 3D-cultured
PHHs.
DISCUSSION
This study confirms that basal mRNA expression and CYP
activity as well as CYP inducibility show large differences between
in vitro used hepatocyte cell models and, depending on the
hepatocyte model used, that the in vivo characterized Basel
phenotyping cocktail is suitable for CYP induction experiments
in vitro.
HepG2 cells represent a hepatoma cell line, which is used
extensively for toxicological studies but less frequently for studies
of drugmetabolism (Yoshitomi et al., 2001; Xu et al., 2004; Zahno
et al., 2011). Drug metabolism is difficult to assess with this
cell line since CYPs show weak mRNA expression and activity
(Donato and Castell, 2003; Westerink and Schoonen, 2007a;
Gerets et al., 2012). In this point, the results of the current
investigation are in agreement with these previous studies. In
Frontiers in Pharmacology | www.frontiersin.org 6 November 2016 | Volume 7 | Article 443
Berger et al. Basel Cocktail In vitro
FIGURE 3 | mRNA expression of CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A4 in HepG2 (A), HepaRG (B), 2D- (C), and 3D-cultured primary cryopreserved human
hepatocytes (D) after treatment with 20 µM rifampicin for 48 h. mRNA expression was determined by rt-PCR as described in the Materials and Methods Section.
Values were normalized to GAPDH expression. Results are expressed as the mean ± SEM fold increase after treatment with rifampicin relative to levels observed in
control cultures. PHH, primary human hepatocytes. *p < 0.05 vs. control culture.
the basal state, mRNA expression was clearly lower than in
the other cell types for every CYP investigated and the activity
could reliably be determined only for CYP3A4 and CYP2C19.
CYP induction with rifampicin resulted in a significant four-
fold increase in the CYP3A4 mRNA, which was only partially
reflected in a corresponding increase in CYP3A4 activity. A
limited inducibility of the CYP3A and CYP2C families in HepG2
cells has also been shown in other studies (Donato and Castell,
2003; Gerets et al., 2012) and has been attributed to a low
expression of the nuclear receptors CAR and PXR (Aninat
et al., 2006; Guillouzo et al., 2007), which are mediating the
induction of the CYP2C and 3A families (Xu et al., 2005). In
contrast, inducibility of CYP1A2 (which we did not determine
in our studies) has been shown to be maintained in HepG2 cells
(Choi et al., 2015). CYP1A2 induction is mediated by the aryl
hydrocarbon receptor (Xu et al., 2005), which is highly expressed
in HepG2 cells (Aninat et al., 2006). In contrast to phase I enzyme
activities, conjugation reactions appear to be maintained quite
well in HepG2 cells (Westerink and Schoonen, 2007b). HepG2
cells can therefore only be used to answer very specific questions
regarding drug metabolism.
HepaRG cells represent a hepatoma cell line, which has first
been described in 2002 as a cell model suitable for HBV infection
and propagation (Gripon et al., 2002). Soon after their first
description, HepaRG cells were characterized and proposed for
their use as a model for drug metabolism studies (Aninat et al.,
2006). The gene expression profile shows profound differences
compared to HepG2 cells, explaining the observed differences in
their drug metabolism phenotype (Jennen et al., 2010). HepaRG
cells have also been used in drug toxicity studies, particularly,
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FIGURE 4 | Formation of paraxanthine (A), 8′-OH-efavirenz (B), E-3174 (C), 5-OH-omeprazole (D), α-OH-metoprolol (E), and 1′-hydroxymidazolam (F) by
3D-cultured primary human hepatocytes after treatment with 20 µM rifampicin for 72 h (open symbols) compared to control cultures (closed symbols). Metabolite
concentrations were determined by LC-MS/MS. The corresponding formation rates and regression coefficients in control cultures and after treatment with 20 µM
rifampicin are given in Tables 2, 3. Data are presented as mean ± SEM of at least three independent experiments.
when active metabolites are suspected (Guillouzo et al., 2007;
Gerets et al., 2012). Considering the current study, HepaRG
cells were clearly a more suitable hepatocyte model for studying
drug metabolism than HepG2 cells. mRNA expression could be
detected for all CYPs investigated and was inducible except for
CYP1A2 and 2D6. Lack of CYP1A2 induction is not a problem
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TABLE 3 | Induced CYP activities.
Induced CYP activities (20 µM rifampicin)
pmol/h/50,000 cells
HepG2 cells HepaRG cells 2D-cultured PHH 3D-cultured PHH
CYP1A2 nd (0.51 ± 0.04) (0.09 ± 0.01) 0.46 ± 0.02
0.956
CYP2B6 nd 1.31 ± 0.04 1.7 ± 0.1 5.7 ± 0.1
0.998 0.975 0.994
CYP2C9 nd (0.12 ± 0.02) (0.022 ± 0.002) 0.41 ± 0.01
0.985
CYP2C19 0.21 ± 0.01 75.9 ± 1.8 1.96 ± 0.11 30.7 ± 1.7
0.979 0.996 0.978 0.980
CYP2D6 nd 3.9 ± 0.2 0.35 ± 0.01 8.6 ± 0.4
0.992 0.928 0.952
CYP3A4 1.1 ± 0.1 675 ± 20 129 ± 8 432 ± 17
0.999 0.999 0.943 0.952
CYP activity in HepG2, HepaRG, 2D-, and 3D-cultured primary cryopreserved human
hepatocytes (PHH) after treatment with 20 µM rifampicin for 72 h. Primary human
hepatocytes used for 2D- and 3D-cultures were from the same batch of cryopreserved
cells. Values presented are the metabolite formation rates and the regression coefficients
(r2 ) of the metabolite-time curves after pre-treatment with rifampicin. Metabolite
concentrations were determined by LC/MS. Data are presented as mean ± SEM of at
least three independent experiments. Values in brackets are based on measurements of
the last experimental time-point only, concentrations of all earlier time-points were below
LLOQ. nd = not determinable (lacking basal activity).
of the cell line, but of rifampicin, which was used as a CYP
inducer. As shown in vitro (Gerets et al., 2012; Choi et al.,
2015) and in vivo (Derungs et al., 2016), rifampicin is a good
inducer for the CYP2C and 3A families, but not for CYP1A2.
With specific CYP1A2 inducers such as 3-methylcholanthrene
CYP1A2 can be induced in HepaRG cells on both the mRNA
and the activity level (Aninat et al., 2006; Guillouzo et al.,
2007). CYP2D6 has a low activity in HepaRG cells, possibly
because the cell line originates from a slow CYP2D6 metabolizer
(Guillouzo et al., 2007), and it cannot be induced with rifampicin
(Gerets et al., 2012).
Interestingly, the activity for CYP3A4 and 2C19 were higher
in HepaRG cells as compared to 3D-cultured PHHs, whereas
the corresponding mRNA expressions (relative to GAPDH)
were lower. This could be a problem of standardization to
GAPDH (different GAPDH expression in HepaRG cells and
primary hepatocytes) or a bad correlation between mRNA
levels and protein expression and/or activity. In the study
of Choi et al. (2015), GAPDH mRNA expression was quite
stable among different hepatocyte cell lines, arguing against the
first possibility. On the other hand, it is well established that
posttranslational modifications such as acetylation, glycosylation,
and phosphorylation can have a large impact on protein activity
(Glanemann et al., 2003), favoring the second possibility. In our
study, the CYP activity profile and inducibility of HepaRG cells
were more closely related to primary hepatocytes than to HepG2
cells.
Primary hepatocytes are currently considered to be the gold
standard for drug metabolism studies. By using the same batch of
human cryopreserved hepatocytes in the 2D- and 3D-cultures,
we were able to estimate whether the 3D environment would
lead to differences in CYP activity and/or expression compared
to the 2D-cultures. Indeed, in comparison to 2D-cultures, 3D-
cultured PHHs exhibited a higher CYP mRNA expression, a
higher basal CYP activity and a better inducibility. In comparison
to the in vivo results regarding CYP induction, 3D-cultured
PHHs showed a better agreement than the other cell lines
tested, suggesting that they could be usable to predict the
induction potential of new drugs. Hepatocyte 3D-cultures are
currently being developed and characterized as an alternative
to 2D-cultures in order to overcome well-known drawbacks
of 2D-cultures such as varying expression of CYP activities,
varying CYP inducibility and loss of differentiation over time
(Aninat et al., 2006; Halladay et al., 2012). Assuming that
3D-cultures of PHHs may offer advantages compared to the
corresponding 2D-cultures, many 3D-hepatocyte models have
been and are currently being explored for drug metabolism
and drug toxicity studies (Godoy et al., 2013; Schyschka
et al., 2013; Astashkina and Grainger, 2014; Roth and Singer,
2014).
We performed our studies with a co-culture system using
3T3-Swiss albino mouse fibroblasts as feeder cells for human
cryopreserved primary hepatocytes. This system has originally
been described in detail by Ohkura et al. (2014) who
characterized it regarding the mRNA expression of phase I
and phase II drug metabolism enzymes and demonstrated
its capacity to produce metabolites from different drugs. The
model uses special plates coated with a block co-polymer
that allows the fibroblasts and hepatocytes to only adhere to
certain areas of the wells. In time, the mouse fibroblasts and
human cryopreserved hepatocytes are able to form 3D structures
described as spheroids. Spheroids can be regarded as a cell
aggregation with an energy- and surface-minimized structure
that, according to van Zijl et al. (van Zijl and Mikulits, 2010)
mimic the in vivo situation quite efficiently regarding cell shape
and cellular environment. The results of our study support this
assumption.
After having been characterized in vivo (Donzelli et al.,
2014; Derungs et al., 2016), the substrate cocktail showed
a satisfactory performance also in vitro. Critical substrates
were losartan (CYP2C9) and caffeine (CYP1A2), which were
metabolized at a low rate even in 3D-cultured PHHs and
showed no significant metabolism in HepG2 cells. On the other
hand, they correctly reflected CYP2C9 induction by rifampicin
and CYP1A2 induction by 3-methylcholanthrene. Depending
on the question to be answered and on the cell system used,
they could be replaced by phenacetin (CYP1A2) and diclofenac
(CYP2C9), which have been shown to be suitable substrates
in vitro (Youdim et al., 2007; Mori et al., 2009; Halladay et al.,
2012).
In conclusion, our studies demonstrate that the 3D-PHH
spheroid culture system is suitable for the assessment of
drug metabolism and CYP induction in vitro. Among the
four tested cell systems, 3D-cultured PHHs best reflect CYP
inducibility in vivo. HepaRG cells are close to 3D-cultured
PHHs but induced CYP activities correlate less well with
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FIGURE 5 | Fold increase (relative to non-induced control) of CYP activity in vitro in HepG2 (A), HepaRG (B), 2D-, and 3D-cultured primary human hepatocytes (C,D),
and in vivo in healthy male subjects (E, n = 14 for CYP2C19 and CYP2D6; n = 15 for all other CYP isoforms) after treatment with rifampicin. Hepatocyte cell lines were
treated with 20 µM rifampicin for 72 h and healthy volunteers with 600mg rifampicin per day for 7 days as described in the Materials and Methods Section. Metabolite
and parent drug concentrations were determined by LC-MS/MS. Results are expressed as mean ± SEM. PHH, primary human hepatocytes. *p < 0.05 vs. control.
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CYP induction in vivo. HepG2 cells are known to predict
CYP1A2 induction but are less suitable for CYPs of the
2C and 3A family. The substrates of the Basel phenotyping
cocktail only show minimal interactions in vitro and the
cocktail is thus usable for the assessment of CYP induction
in vitro.
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Supplementary Figure 2 | Chemical structures of the probe drugs and
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